References
- Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69(3):562–73.
- Sri Manjari K, Pratibha Nallari A, Vidyasagar, Plasma TGF-b1, MMP-1 and MMP-3 levels in chronic pancreatitis. Ind J Clin Biochem 2012;27(2):152–6.
- Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13(8):781–92.
- Arakaki PA, Marques MR, Santos MC. MMP-1 polymorphism and its relationship to pathological processes. J Biosci 2009;34(2):313–20.
- Conant K, Haughey N, Nath A, Matrix metalloproteinase-1 activates a pertussis toxin-sensitive signaling pathway that stimulates the release of matrix metalloproteinase-9. J Neurochem 2002;82(4):885–93.
- Lee EJ, Woo MS, Moon PG, Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 2010;185(1):615–23.
- Leake A, Morris CM, Whateley J. Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neurosci Lett 2000;291(3):201–3.
- Lorenzl S, Albers DS, Chirichigno JW, Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. J Neurol Sci 2004;218(1–2):39–45.
- Lorenzl S, Albers DS, Narr S, Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol 2002;178(1):13–20.
- Vos CM, Sjulson L, Nath A, Cytotoxicity by matrix metalloprotease-1 in organotypic spinal cord and dissociated neuronal cultures. Exp Neurol 2000;163(2): 324–30.
- Conant K, St Hillaire C, Nagase H, Matrix metalloproteinase 1 interacts with neuronal integrins and stimulates dephosphorylation of Akt. J Biol Chem. 2004;279(9): 8056–62.
- Hamill CE, Caudle WM, Richardson JR, Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1. Mol Pharmacol 2007;72(3): 653–64.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.
- Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999; 274(31):21491–4.
- Bendotti C, Tortarolo M, Borsello T. Targeting stress activated protein kinases, JNK and p38, as new therapeutic approach for neurodegenerative diseases. Central Nervous System Agents in Med Chem 2006;6(2):109–17.
- Endo H, Utani A, Shinkai H. Activation of p38 MAPK suppresses matrix metalloproteinase-1 gene expression induced by platelet-derived growth factor. Arch Dermatol Res 2003;294(12):552–8.
- Singer CF, Marbaix E, Kokorine I, The matrix metalloproteinase-1 (MMP-1) expression in the human endometrium is inversely regulated by interleukin-1 alpha and sex steroids. Ceska Gynekol 2000;65(4):211–5.